Turkey: Protection of Second Medical Use Patents in Turkey

Last Updated: 2 November 2015
Practice Guide by Deris IP Attorneys
  • Introduction

It is commonly known that pharmaceutical patents cover the substance or the composition itself (molecule patents) and the use of this substance or composition in the treatment of a disease (indication patents). 

In pharmaceutical patents, the new and non-obvious use of a known substance or composition for the manufacture of a medicament in the treatment of a specific disease is called as second or further medical use patents. The simplest example that can be mentioned for the second medical use patents is the patenting of an invention when a medicament with an active substance X known to be effective in the treatment of hypertension is also found to be effective in the treatment of common cold upon the further researches conducted.

  1. Status of Second Medical Use in Turkey

In accordance with Transitional Article 4 of Decree Law No. 551 on the Protection of Patents (Decree Law No. 551), the protection pertaining to pharmaceutical products within the scope of this Decree Law commenced on January 1, 1999.

On the other hand Turkey signed the 1973 dated European Patent Convention (EPC 1973) on October 5, 1973, which provided protection for pharmaceutical patents. Although Turkey was one of the first states that signed the EPC 1973, this convention entered into force much later upon the publication of the law for accession to the convention and its annexes in the Official Gazette dated July 12, 2000.1

The act revising EPC 1973 was signed as a result of the diplomatic conference held in November 2000.2 This revision act is called EPC 2000. Turkey attended this diplomatic conference and signed the Revision Act. EPC 2000 which came into force on December 13, 2007; 2 years after the 15th contracting state deposited its instrument of ratification to the German Government.

Article 54/5 added to the convention by the EPC 2000 revision, explicitly states that specific use in any method referred to in Art. 53(c) provided that such use is not comprised in the state of the art, is patentable. According to this provision the use of a prior art substance and composition in the treatment of a new disease has become possible.

Despite the lack of a provision stating explicitly the patentability of second medical use patents in EPC 1973; it has been decided that the use of a known substance or composition for the manufacture of a medicament for a specific new and inventive therapeutic application is patentable by the G5/83 decision of the EPO Enlarged Board of Appeal.3

There have been opinions claiming that the G5/83 decision of the Enlarged Board of Appeal is not binding for the contracting states of the EPC and that the second medical use patents granted before December 13, 2007 - i.e. before EPC 2000 came into force - are invalid.4

Contrary to the mentioned opinions, the authors of this article believe that, as far as Turkey is concerned, the decisions and opinions of the Enlarged Board of Appeal are the inseparable parts of the EPC 1973 because the Turkish Parliament acknowledged the developments with regard to the European Patent Convention since 1973 and approved the accession to the EPC 1973 on January 29, 2000 by ratifying it without any reservations. EPC 1973 and the decisions of the Enlarged Board of Appeal have been published together, in their entirety, in the Official Gazette. The fact that the Parliament acknowledged and voted the EPC 1973 together with the decisions of the Enlarged Board of Appeal without reservations; renders unquestionable the will of the Parliament to afford protection to patents covering second and further medical use on the basis of the international legislation of which Turkey is signatory and which has thus become national rule by Act of Parliament.

  1. Evaluation of Second Medical Use Patents According to Decree Law No. 551 on the Protection of Patents:

Decree Law No.551 remains silent since second medical use patents are not accepted as "patentable" or "non-patentable". Neither there is a provision stating that second medical use patents are not subject to protection nor there is a distinction between first and second medical use patents in the Decree Law No. 551. Hence, in its practices, the Turkish Patent Institute grants second medical use patents provided that they meet the patentability criteria.

  1. Evaluation of Second Medical Use Patents According to the TRIPs Agreement:

TRIPs does not indicate any prohibition for the protection of second medical use patents.

  1. Evaluation of Second Medical Use Patents According to EPC 1973:

There is no provision in EPC 1973 that restricts patentability of inventions on second medical use.

According to Article 52 (1) of EPC 1973 titled “Patentable Inventions” “European patents shall be granted for any inventions which are susceptible of industrial application, which are new and which involve an inventive step.

Paragraph 2 of the same article states that “the following in particular shall not be regarded as inventions:

“(2) The following in particular shall not be regarded as inventions within the meaning of paragraph 1:

(a)discoveries, scientific theories and mathematical methods;

(b)aesthetic creations;

(c)schemes, rules and methods for performing mental acts, playing games or doing business, and programs for computers;

(d)presentations of information.

(3)The provisions of paragraph 2 shall exclude patentability of the subject-matter or activities referred to in that provision only to the extent to which a European patent application or European patent relates to such subject-matter or activities as such.

(4)*Methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body shall not be regarded as inventions which are susceptible of industrial application within the meaning of paragraph 1. This provision shall not apply to products, in particular substances or compositions, for use in any of these methods.

Ref: Art. 54, 56, 57, 100, 138

*See decisions of the Enlarged Board of Appeal G 1/83G 5/83G 6/83G 1/98G 1/03G 2/03 (Annex I)..”

As understood from Article 52/4 above, this provision shall not be applied to methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body. This provision excludes the medical use of a substance or composition from non-patentable subject matters. There are no distinctions between first and second medical use patents.

In Article 53 titled “Exceptions to patentability” of EPC 1973 the subjects which shall not be patented are listed as follows:

Article 53- Exceptions to patentability

European patents shall not be granted in respect of:

(a) inventions the publication or exploitation of which would be contrary to "ordre public" or morality, provided that the exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting States;

(b) plant or animal varieties or essentially biological processes for the production of plants or animals; this provision does not apply to microbiological processes or the products thereof.

Ref: Art. 100, 138, 167*”

As shall be understood in the provisions of the article above, second medical use and medical use in general have not been listed among subjects that shall not be patented. Thus, there are no provisions stating that inventions subject to second medical use will not be protected in the scope of EPC 1973.

Article 54 of EPC 1973 titled “Novelty” reads:

Article 54 - Novelty

(1) An invention shall be considered to be new if it does not form part of the state of the art.

(2) The state of the art shall be held to comprise everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the European patent application.

(3) Additionally, the content of European patent applications as filed, of which the dates of filing are prior to the date referred to in paragraph 2 and which were published under Article 93 on or after that date, shall be considered as comprised in the state of the art.

(4) Paragraph 3 shall be applied only in so far as a Contracting State designated in respect of the later application, was also designated in respect of the earlier application as published.

(5) The provisions of paragraphs 1 to 4 shall not exclude the patentability of any substance or composition, comprised in the state of the art, for use in a method referred to in Article 52, paragraph 4, provided that its use for any method referred to in that paragraph is not comprised in the state of the art.

Ref: Art. 52, 55, 56, 80, 85, 89, 100, 138, 158, Rules 27, 44, 87

* See decisions/opinions of the Enlarged Board of

Appeal G 1/83G 5/83G 6/83G 2/88G 6/88,G 1/92G 3/93 (Annex I).”

Paragraph 5 of this article explicitly accepts the use of a known substance or composition in a therapeutic application on the condition that it is new and inventive.

The G5/83 decision of the EPO Enlarged Board of Appeal is referenced in articles 52 and 54 of the EPC 1973.

The G5/83 decision is listed in the “Index of decisions and opinions of the Enlarged Board of Appeal published in the Official Journal of the EPO”. The index of decisions and opinions is published as Annex-I of the EPC 1973 in the Official Gazette no. 24107 dated July 12, 2000. The index, relates the decision and opinion of the Enlarged Board of Appeal to the articles of the EPC 1973. The respective part of the index of decisions is quoted below:

Index of Decisions and Opinions of the Enlarged Board of Appeal Published in the Official Journal of the EPO

Case number, date, publication

Title/Subject

Article no.,

Rule no.

G 5/83

05.12.1984

European Patent Office Official Journal 1985, 64

“Second medical indication/EISAI”

Interpretation of EPC/Vienna Convention – use claims regarding treatment

Art. 52(1), 52(4), 54(5), 57 Articles 31, 32 of the Vienna Convention

The G5/83 decision of the EPO Enlarged Board of Appeal explains in detail how to interpret Articles 52 (4) and 54 (5) of the EPC 1973 and that a claim for the use of a known substance or composition in the manufacture of a medicament for a new therapeutic application is patentable.

The Turkish Parliament accepted the accession of Turkey to the EPC 1973 by the Act dated January 27, 2000 and No.: 4504. EPC 1973 entered into force upon its publication in the Official Gazette no. 24107 dated July 12, 2000. 

It is obvious that the lawmaker namely the Parliament by the Act January 27, 2000 dates accepts the interpretation of the articles of EPC 1973 with the decisions and opinions of the Enlarged Board of Appeal which are published as inseparable annexes to the convention in the Turkish Official Gazette5. The aim of the lawmaker is that the interpretation of Articles 52 and 54 should be made in the light of the G5/83 decision which is an obvious annex of the Agreement to which Turkey is a party.

A contrary approach to EPC 1973, will be against the national legislation of Turkey and the provisions of the international conventions entered into force in Turkey and against Article 90/56  of the Constitution and Article 47 of the Decree Law No. 551.

  • Conclusion

As far as Turkey is concerned, the decisions and opinions of the Enlarged Board of Appeal are the inseparable parts of the EPC 1973 because the Turkish lawmaker observed the developments with regard to the European Patent Convention since 1973 approved and voted the accession to the EPC 1973 on January 29, 2000 by ratifying it without any reservations and publishing it in the Official Gazette in their entirety together with the Enlarged Board of Appeal decisions.


Footnotes

1 Official Gazette No. 24107 dated July 2, 2000:

http://www.resmigazete.gov.tr/main.aspx?home=http://www.resmigazete.gov.tr/eskiler/2000/07/20000712m1.htm&main=http://www.resmigazete.gov.tr/eskiler/2000/07/20000712m1.htm

2 ACT REVISING THE CONVENTION ON THE GRANT OF EUROPEAN PATENTS: http://documents.epo.org/projects/babylon/eponet.nsf/0/879B3BBE83D923B0C12572AE004FE772/$File/ACT REVISING THE CONVENTION ON THE GRANT OF EUROPEAN PATENTS: http://documents.epo.org/projects/babylon/eponet.nsf/0/879B3BBE83D923B0C12572AE004FE772/$File/act_revising_epc_en.pdf

3 European Patent Office Official Journal, 1985, p. 060: G1/83 German, G5/83 English, G6/83 French

http://documents.epo.org/projects/babylon/eponet.nsf/0/5891FCEDA0C96A07C12572C8006C5110/$File/http://documents.epo.org/projects/babylon/eponet.nsf/0/5891FCEDA0C96A07C12572C8006C5110/$File/g830001.pdf

4 Hazal Zengingül, Ankara 2012, Fikri Mülkiyet Hukuku Yıllığı 2011, İkinci Tıbbi Kullanım Patentleri (Second Medical Use Patents), 447

Av. Ece Sarıca, Nisan 2015, İstanbul Barosu Dergisi Mart – Nisan 2015, Türkiye’de İkinci Tıbbi Kullanımın Patentlenmesi ve Korunması (Patenting and Protection of Second Medical Use in Turkey), 392

5 See footnote 1.

6 Article 90/5 of the 1982 Constitution of the Republic of Turkey: International agreements duly put into effect have the force of law. No appeal to the Constitutional Court shall be made with regard to these agreements, on the grounds that they are unconstitutional. In the case of a conflict between international agreements, duly put into effect, concerning fundamental rights and freedoms and the laws due to differences in provisions on the same matter, the provisions of international agreements shall prevail.

7 Article 4 of Decree Law No. 551: Where International Agreements having entered into force according to the laws of the Republic of Turkey, contain provisions which are preferential/more favorable to those of this present Decree-Law, the persons referred to in Article 2 may request to benefit from such preferential/more favorable provisions.

This document is not intended to create an attorney-client relationship. You should not act or rely on any information in this document without first seeking legal advice. This material is intended for general information purposes only and does not constitute legal advice. If you have any specific questions on any legal matter, you should consult a professional legal services provider.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Contact the Author?
Click here to email the Author
View Template
Click to View the Template
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Supporting Documents
Other Turkey Advice Centres
Competition and Antitrust
Tax
Privacy and Data Protection
More Advice Centers
Useful Resources
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
The national Turkey group for the International Association for the Protection of Intellectual Property.
Upcoming Events
This site provides access to information about meetings held at WIPO and related documents comprising a detailed meeting calendar and a powerful document search facility.
A calendar of past and future events held by the Turkish Patent Institute.
Information about events and classroom training, online training, the European qualifying examination, and other materials.
From the Annual Meeting to local forums, roundtables and digital learning, INTA's Programs and Events help you stay up to date on issues that affect your brands.
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.